Shares of Sage Therapeutics (NASDAQ:SAGE) fell 18% post-market after the company released its Q3 earnings report and said ...

专注于脑健康疾病的生物制药公司Sage Therapeutics股价触及52周新低，跌至5.63美元。这一价格点反映了该公司的显著下滑，过去一年股价变动幅度达-70.71%。由于公司正经历临床试验挫折和生物科技股整体市场下滑的艰难时期，投资者保持谨慎态度。跌至今年最低点凸显了该板块的波动性以及市场对Sage业绩和前景的反应。 在其他近期新闻中，Sage Therapeutics报告其产后抑郁症(P ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus ...

The Sage Group Plc engages in the provision of ... and North America. The company was founded by David Goldman, Paul Muller, and Graham Wylie in 1981 and is headquartered in Newcastle-upon-Tyne ...

The Cambridge, Mass.-based company SAGE said it would give priority to the launch of zurzuvae, a treatment for postpartum depression, and focus on a study readout from its dalzanemdor as a ...

Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple setbacks to its pipeline. The job cuts will affect about one-third of its ...

J.P. Morgan analyst Anupam Rama maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on November 6 and set a price ...

Shares of Sage Group PLC SGE inched up 0.80% to £10.78 Thursday, on what proved to be an all-around positive trading session ...

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company specializing in central nervous system (CNS) disorders, finds itself at a critical juncture as it navigates the competitive ...

The discontinuation of SAGE-324, due to tolerability issues, has led the company to shift its focus to other early-stage assets. Among these is SAGE-319, an extra-synaptic preferential GABA PAM ...

Ritu Baral has given his Hold rating due to a combination of factors related to SAGE Therapeutics’ strategic decisions and organizational changes. The company’s decision to reorganize is seen ...